User login
Article Type
Changed
Wed, 05/26/2021 - 13:58
Display Headline
Rectal cancer management in elderly patients: experience of a single Portuguese institution
Background The incidence of rectal cancer increases with age, and older patients are more likely to have other chronic conditions that can affect outcome and tolerability of treatment.
Objective To evaluate retrospectively the influence of age and comorbidities in the management of rectal cancer.
Methods 59 patients aged 75 years and older with stage II-III rectal cancer who were treated during a 3-year period were included in the study. Comorbidities were assessed using the Charlson Comorbidity Index (CCI) and the patients were divided into 2 groups based on their CCI scores: Fit (score of 0-1 points) and Vulnerable (score of ≥ 2). Primary endpoint was survival at 1 and 3 years.
Results The sample included 43 patients (72.9%) in the Fit group and 16 patients (27.1%) in the Vulnerable group. The most common comorbidities were myocardial infarction, diabetes, and chronic lung disease. One-year survival the same between the groups (P = .330), but 3-year survival was lower in the Vulnerable group patients (83.7% vs 56.3%, respectively; P = .040). The rates of neoadjuvant chemo- and radiotherapy use and low anterior resection performance were the same between the groups. Colostomy closure was achieved more frequently in the Fit group compared with the Vulnerable group (83.3% vs 55.6%; P = .083). There was no difference in mean disease-free survival, grade 3-4 toxicity, and dose reduction between the groups.
Conclusions Comorbidity assessment should always be included in standard oncological management of elderly patients. Fit patients can be managed with standard treatment and may benefit from a conventional, more aggressive approach in their therapy.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 13(1)
Page Number
8-13
Legacy Keywords
rectal cancer, Charlson Comorbidity index, CCI
Sections
Article PDF
Article PDF
Background The incidence of rectal cancer increases with age, and older patients are more likely to have other chronic conditions that can affect outcome and tolerability of treatment.
Objective To evaluate retrospectively the influence of age and comorbidities in the management of rectal cancer.
Methods 59 patients aged 75 years and older with stage II-III rectal cancer who were treated during a 3-year period were included in the study. Comorbidities were assessed using the Charlson Comorbidity Index (CCI) and the patients were divided into 2 groups based on their CCI scores: Fit (score of 0-1 points) and Vulnerable (score of ≥ 2). Primary endpoint was survival at 1 and 3 years.
Results The sample included 43 patients (72.9%) in the Fit group and 16 patients (27.1%) in the Vulnerable group. The most common comorbidities were myocardial infarction, diabetes, and chronic lung disease. One-year survival the same between the groups (P = .330), but 3-year survival was lower in the Vulnerable group patients (83.7% vs 56.3%, respectively; P = .040). The rates of neoadjuvant chemo- and radiotherapy use and low anterior resection performance were the same between the groups. Colostomy closure was achieved more frequently in the Fit group compared with the Vulnerable group (83.3% vs 55.6%; P = .083). There was no difference in mean disease-free survival, grade 3-4 toxicity, and dose reduction between the groups.
Conclusions Comorbidity assessment should always be included in standard oncological management of elderly patients. Fit patients can be managed with standard treatment and may benefit from a conventional, more aggressive approach in their therapy.
Click on the PDF icon at the top of this introduction to read the full article.
Background The incidence of rectal cancer increases with age, and older patients are more likely to have other chronic conditions that can affect outcome and tolerability of treatment.
Objective To evaluate retrospectively the influence of age and comorbidities in the management of rectal cancer.
Methods 59 patients aged 75 years and older with stage II-III rectal cancer who were treated during a 3-year period were included in the study. Comorbidities were assessed using the Charlson Comorbidity Index (CCI) and the patients were divided into 2 groups based on their CCI scores: Fit (score of 0-1 points) and Vulnerable (score of ≥ 2). Primary endpoint was survival at 1 and 3 years.
Results The sample included 43 patients (72.9%) in the Fit group and 16 patients (27.1%) in the Vulnerable group. The most common comorbidities were myocardial infarction, diabetes, and chronic lung disease. One-year survival the same between the groups (P = .330), but 3-year survival was lower in the Vulnerable group patients (83.7% vs 56.3%, respectively; P = .040). The rates of neoadjuvant chemo- and radiotherapy use and low anterior resection performance were the same between the groups. Colostomy closure was achieved more frequently in the Fit group compared with the Vulnerable group (83.3% vs 55.6%; P = .083). There was no difference in mean disease-free survival, grade 3-4 toxicity, and dose reduction between the groups.
Conclusions Comorbidity assessment should always be included in standard oncological management of elderly patients. Fit patients can be managed with standard treatment and may benefit from a conventional, more aggressive approach in their therapy.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 13(1)
Issue
The Journal of Community and Supportive Oncology - 13(1)
Page Number
8-13
Page Number
8-13
Article Type
Display Headline
Rectal cancer management in elderly patients: experience of a single Portuguese institution
Display Headline
Rectal cancer management in elderly patients: experience of a single Portuguese institution
Legacy Keywords
rectal cancer, Charlson Comorbidity index, CCI
Legacy Keywords
rectal cancer, Charlson Comorbidity index, CCI
Sections
Citation Override
JCSO 2015;13:8-13
Disallow All Ads
Alternative CME
Article PDF Media
Document